Moderna, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Moderna, Inc. (MRNA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $523.50 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-13
- Moderna, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $523.50M, a 517.49% increase from fiscal 2017.
- Moderna, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $84.78M.
- Moderna, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$108.96M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|
| 2018-12-31 | $523.50M 10-K · filed 2019-03-13 |
| 2017-12-31 | $84.78M 10-K · filed 2019-03-13 |
| 2016-12-31 | -$108.96M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |